RedHill Biopharma Ltd. Sponsored ADR RDHL 深 沪
等待开盘 03-31 09:30:00 美东时间
0.7447
-0.005
-0.71%
华盛通- 最 高0.79
- 今 开0.79
- 成交量 5.13万股
- 最 低 0.7101
- 昨 收 0.75
- 总市值 380.76万
- 52周最高 3.3099
- 市盈率 静 0.01
- 换手率 1.00%
- 52周最低 0.7101
- 委 比 47.06%
- 总股本 511.29万
- 历史最高 22220.00
- 量 比 2.60
- 振 幅 10.65%
- 历史最低 0.7101
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled
02-25 20:11
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.
01-06 23:26
RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.
RedHill Biopharma shares are trading higher after the company announced develop...
01-05 23:44
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroen...
01-05 20:00
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, wit...
2025-12-15 20:00
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced th...
2025-12-01 20:00
RedHill Biopharma Wins ~$10.5M Judgment Against Kukbo; RedHill Has Secured A Korean Court Attachment Grant Against Kukbo Aimed At Preventing Kukbo From Disposing Of Assets Prior To Judgment Enforcement
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd
2025-11-04 22:34
RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost
RedHill Biopharma ( ($RDHL) ) has provided an announcement. On October 16, 2025...
2025-10-23 05:17
RedHill receives Nasdaq staff determination notification
RedHill Biopharma (NASDAQ:RDHL) said it received a Nasdaq Staff Determination notice on October 16 stating the company failed to meet the minimum $2.5 million stockholders’ equity requirement for cont...
2025-10-23 04:54
